Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTB4R | Q15722 | 1/20 | 0.50 |
| ▸ | LTB4R2 | Q9NPC1 | 1/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 8/20 | 0.45 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.45 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | HTT | P42858 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28467850 | 0.85 | CHRNB2 (0.56) | LTB4RLTB4R2CYP2D6KDM4EALDH1A1 | |
| SCHEMBL2768717 | 0.82 | SLC7A5 (0.48) | SIGMAR1KDM4EALDH1A1HTTSMN1; SMN2 | |
| SCHEMBL2767522 | 0.82 | SLC7A5 (0.48) | CYP2D6KCNH2KDM4EALDH1A1HTT | |
| SCHEMBL25495948 | 0.81 | KDM4E (0.56) | CYP2D6KDM4EALDH1A1SMN1; SMN2LMNA | |
| SCHEMBL13849587 | 0.81 | LTA4H (0.51) | LTB4RLTB4R2CYP2D6KCNH2KDM4E | |
| SCHEMBL14025120 | 0.81 | ACHE (0.49) | CYP2D6KDM4E | |
| SCHEMBL4591522 | 0.78 | KDM4E (0.52) | KDM4EALDH1A1SMN1; SMN2LMNASLC7A5 | |
| SCHEMBL28588436 | 0.78 | KMT2A (0.55) | CYP2D6KCNH2KDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL3334714 | 0.78 | ALDH1A1 (0.51) | CYP2D6KDM4EALDH1A1SMN1; SMN2SLC7A5 | |
| SCHEMBL27174647 | 0.78 | SMN1; SMN2 (0.51) | LTB4RLTB4R2KDM4EALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080269240-A1 | Novel Adenine Compound | Dainippon Sumitomo Pharma Co., Ltd. a corporation of Japan (JP) | 2008-10-30 | — | — | US | disclosed |
| US-20080269240-A1 | Novel Adenine Compound | Dainippon Sumitomo Pharma Co., Ltd. a corporation of Japan (JP) | 2008-10-30 | — | — | US | disclosed |
| US-20080269240-A1 | Novel Adenine Compound | Dainippon Sumitomo Pharma Co., Ltd. a corporation of Japan (JP) | 2008-10-30 | — | — | US | disclosed |
| EP-1939199-A1 | NOVEL ADENINE COMPOUND | Dainippon Sumitomo Pharma Co., Ltd. (JP) | 2008-07-02 | — | — | EP | disclosed |
| EP-1939199-A1 | NOVEL ADENINE COMPOUND | Dainippon Sumitomo Pharma Co., Ltd. (JP) | 2008-07-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080269240-A1 | Novel Adenine Compound | ADORA1, ADORA2A, ADORA3 | LTB4R 969/4885LTB4R2 599/4885CYP2D6 180/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.